OKYO Pharma is all set to commence a clinical trial for dry eye treatment in the US

Activation of First Clinical Trial Site in the U.S

OKYO Pharma Ltd, a biotech company focused on ophthalmology, has announced the activation of its first clinical trial site in the United States for phase II trials of its dry eye disease treatment, OK-101.

About OK-101

OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease.

OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

The trial will be multi-centred, randomised, double-blinded, and placebo-controlled, and the first patient is expected to be accepted within two weeks.

With approximately 700 million people worldwide suffering from this chronic ocular condition, the drug candidate aims to address a significant unmet need in the multi-billion-dollar dry eye disease market. Using membrane-anchored-peptide technology, OK-101 has demonstrated anti-inflammatory and pain-reducing activities in mouse models with dry eye disease and corneal neuropathic pain.

The candidate drug molecule includes a lipid anchor to combat washout and enhance time on the eyeball. Gary Jacob, CEO of OKYO Pharma, anticipates that clinical evaluation will be completed by year-end.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.